A recent independent study cites using HemaCare-sourced immune cells to investigate a protein involved in gene activation during hematopoietic stem cell (HSC) development. 
The study, published by scientists at the Yokohama Institute in Japan, is focused on the function of a protein known as RUNX1. The reason RUNX1 is of particular interest is that it’s implicated in the development of a number of different types of cancer, including breast cancer, skin cancer, and acute myeloid leukemia.  In the latter case, defects in the gene that codes for the RUNX1 protein disrupt stem cell differentiation. This means that instead of normal development into mature cell types, there is a massive build-up of blast cells in the bone marrow, which is the hallmark of leukemia. Scientists have known since 2001  that the RUNX1 protein is involved in the differentiation of hematopoietic stem cells into mature blood cells. But in order to target RUNX1’s role in cancer development, researchers need a much more in-depth knowledge of exactly how the protein is exerting its function.